Trial · NCT04070326
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Baseline Observation-12 Weeks Before TP | STARTED | Lanadelumab 150 mg: Age 2 to <6 Years | 4 | |
| Baseline Observation-12 Weeks Before TP | STARTED | Lanadelumab 150 mg: Age 6 to <12 Years | 17 | |
| Baseline Observation-12 Weeks Before TP | COMPLETED | Lanadelumab 150 mg: Age 2 to <6 Years | 4 | |
| Baseline Observation-12 Weeks Before TP | COMPLETED | Lanadelumab 150 mg: Age 6 to <12 Years | 17 | |
| Baseline Observation-12 Weeks Before TP | NOT COMPLETED | Lanadelumab 150 mg: Age 2 to <6 Years | 0 | |
| Baseline Observation-12 Weeks Before TP | NOT COMPLETED | Lanadelumab 150 mg: Age 6 to <12 Years | 0 | |
| Treatment Period A (Weeks 1 to 26) | STARTED | Lanadelumab 150 mg: Age 2 to <6 Years | 4 | |
| Treatment Period A (Weeks 1 to 26) | STARTED | Lanadelumab 150 mg: Age 6 to <12 Years | 17 | |
| Treatment Period A (Weeks 1 to 26) | COMPLETED | Lanadelumab 150 mg: Age 2 to <6 Years | 3 | |
| Treatment Period A (Weeks 1 to 26) | COMPLETED | Lanadelumab 150 mg: Age 6 to <12 Years | 17 | |
| Treatment Period A (Weeks 1 to 26) | NOT COMPLETED | Lanadelumab 150 mg: Age 2 to <6 Years | 1 | |
| Treatment Period A (Weeks 1 to 26) | NOT COMPLETED | Lanadelumab 150 mg: Age 6 to <12 Years | 0 | |
| Treatment Period B (Weeks 27 to 52) | STARTED | Lanadelumab 150 mg: Age 2 to <6 Years | 3 | |
| Treatment Period B (Weeks 27 to 52) | STARTED | Lanadelumab 150 mg: Age 6 to <12 Years | 17 | |
| Treatment Period B (Weeks 27 to 52) | COMPLETED | Lanadelumab 150 mg: Age 2 to <6 Years | 3 | |
| Treatment Period B (Weeks 27 to 52) | COMPLETED | Lanadelumab 150 mg: Age 6 to <12 Years | 17 | |
| Treatment Period B (Weeks 27 to 52) | NOT COMPLETED | Lanadelumab 150 mg: Age 2 to <6 Years | 0 | |
| Treatment Period B (Weeks 27 to 52) | NOT COMPLETED | Lanadelumab 150 mg: Age 6 to <12 Years | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04070326/flow